Vitamin K therapy to improve vascular health in patients with chronic kidney disease

Not Applicable

Completed

• Conditions: Chronic kidney disease stages 3b and 4; Urological and Genital Diseases

• Registration Number: ISRCTN21444964
• Lead Sponsor: Tayside Academic Science Centre (NHS Tayside and University of Dundee)

Brief Summary

2020 results in https://pubmed.ncbi.nlm.nih.gov/32817311/ (added 24/08/2020)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-02-24
• Study Completion: 2019-03-31
• Last Update Posted: 7 September 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 159

Inclusion Criteria

1. Age >18 years
2. CKD stages 3b or 4 (eGFR of >15 ml/min and <45 ml/min by MDRD4 equation)

Exclusion Criteria

1. Atrial fibrillation
2. Taking warfarin (which antagonises vitamin K) or other coumadin derivatives.
3. Taking vitamin K
4. Unable to give written informed consent
5. Currently enrolled in another trial, or within 30 days of completing another trial
6. Pregnant or (if female and pre-menopausal) not using reliable contraception

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Between-group difference in carotid-femoral pulse wave velocity (PWV) at 12 months using the Sphygmocor system